Reply to C. Ren et al

Glenn Heller; Robert McCormack; Thian Kheoh; Arturo Molina; Matthew R. Smith; Robert Dreicer; Fred Saad; Ronald De Wit; Dana T. Aftab; Mohammed Hirmand; Ana Limon-Carrera; Karim Fizazi; Martin Fleisher; Johann S. De Bono; Howard I. Scher

doi:10.1200/JCO.2018.78.2672

Reply to C. Ren et al

Glenn Heller, Robert McCormack, Thian Kheoh, Arturo Molina, Matthew R. Smith, Robert Dreicer, Fred Saad, Ronald De Wit, Dana T. Aftab, Mohammed Hirmand, Ana Limon-Carrera, Karim Fizazi, Martin Fleisher, Johann S. De Bono, Howard I. Scher

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

langue originale	Anglais
Pages (de - à)	2354-2355
Nombre de pages	2
journal	Journal of Clinical Oncology
Volume	36
Numéro de publication	22
Les DOIs	https://doi.org/10.1200/JCO.2018.78.2672
état	Publié - 1 août 2018

Accès au document

10.1200/JCO.2018.78.2672

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{e79f3ea78385427887e2e37ff842860d,

title = "Reply to C. Ren et al",

author = "Glenn Heller and Robert McCormack and Thian Kheoh and Arturo Molina and Smith, {Matthew R.} and Robert Dreicer and Fred Saad and {De Wit}, Ronald and Aftab, {Dana T.} and Mohammed Hirmand and Ana Limon-Carrera and Karim Fizazi and Martin Fleisher and {De Bono}, {Johann S.} and Scher, {Howard I.}",

note = "Funding Information: Supported by National Institutes of Health (NIH; Grant No. P30-CA008748 to G.H., M.F., and H.I.S.; NIH Specialized Programs of Research Excellence Grant No. P50-CA92629 to G.H. and H.I.S.; and NIH Grant No. R01-CA207220 to G.H. and H.I.S.); the Sidney Kimmel Center for Prostate and Urologic Cancers (grant to H.I.S.); Prostate Cancer Foundation (grant to G.H. and H.I.S.); and Department of Defense Prostate Cancer Research Program (Grant No. PC121111 to G.H. and H.I.S.). The COU-AA-301 study and related publications were supported by Ortho Biotech Oncology Research and Development (a unit of Cougar Biotechnology) and grants from the Medical Research Council of the United Kingdom, MOVEMBER Centre of Excellence funding, Experimental Cancer Medical Centre. The AFFIRM (Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-Based Chemotherapy) study and related publications were supported by Medivation and Astellas Pharma Global Development. The ELM-PC-5 study and related publications were supported by Takeda Pharmaceuticals. The ELM-PC-4 study/publication was supported by Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals. The COMET-1 study and related publications were supported by Exelixis. Presented in part at the ASCO Annual Meeting, Chicago, IL, June 2-6, 2017. A.M.{\textquoteright}s current affiliation is Sutro Biopharma, South San Francisco, CA.",

year = "2018",

month = aug,

day = "1",

doi = "10.1200/JCO.2018.78.2672",

language = "English",

volume = "36",

pages = "2354--2355",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

number = "22",

}

TY - JOUR

T1 - Reply to C. Ren et al

AU - Heller, Glenn

AU - McCormack, Robert

AU - Kheoh, Thian

AU - Molina, Arturo

AU - Smith, Matthew R.

AU - Dreicer, Robert

AU - Saad, Fred

AU - De Wit, Ronald

AU - Aftab, Dana T.

AU - Hirmand, Mohammed

AU - Limon-Carrera, Ana

AU - Fizazi, Karim

AU - Fleisher, Martin

AU - De Bono, Johann S.

AU - Scher, Howard I.

N1 - Funding Information: Supported by National Institutes of Health (NIH; Grant No. P30-CA008748 to G.H., M.F., and H.I.S.; NIH Specialized Programs of Research Excellence Grant No. P50-CA92629 to G.H. and H.I.S.; and NIH Grant No. R01-CA207220 to G.H. and H.I.S.); the Sidney Kimmel Center for Prostate and Urologic Cancers (grant to H.I.S.); Prostate Cancer Foundation (grant to G.H. and H.I.S.); and Department of Defense Prostate Cancer Research Program (Grant No. PC121111 to G.H. and H.I.S.). The COU-AA-301 study and related publications were supported by Ortho Biotech Oncology Research and Development (a unit of Cougar Biotechnology) and grants from the Medical Research Council of the United Kingdom, MOVEMBER Centre of Excellence funding, Experimental Cancer Medical Centre. The AFFIRM (Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-Based Chemotherapy) study and related publications were supported by Medivation and Astellas Pharma Global Development. The ELM-PC-5 study and related publications were supported by Takeda Pharmaceuticals. The ELM-PC-4 study/publication was supported by Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals. The COMET-1 study and related publications were supported by Exelixis. Presented in part at the ASCO Annual Meeting, Chicago, IL, June 2-6, 2017. A.M.’s current affiliation is Sutro Biopharma, South San Francisco, CA.

PY - 2018/8/1

Y1 - 2018/8/1

UR - http://www.scopus.com/inward/record.url?scp=85050716855&partnerID=8YFLogxK

U2 - 10.1200/JCO.2018.78.2672

DO - 10.1200/JCO.2018.78.2672

M3 - Letter

C2 - 29894273

AN - SCOPUS:85050716855

SN - 0732-183X

VL - 36

SP - 2354

EP - 2355

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 22

ER -